Rossari Biotech Limited (NSE:ROSSARI)
India · Delayed Price · Currency is INR 429.00
+12.10 (2.90%)
Oct 22, 2026, 3:29 PM IST
Rossari Biotech Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 26,613 | 23,964 | 20,803 | 18,306 | 16,559 | 14,830 | |
Revenue Growth | 19.76% | 15.19% | 13.64% | 10.55% | 11.66% | 109.06% |
Cost of Revenue | 18,734 | 16,774 | 14,393 | 13,007 | 11,765 | 11,121 |
Gross Profit | 7,879 | 7,189 | 6,410 | 5,298 | 4,794 | 3,708 |
Selling, General & Admin | 1,742 | 1,618 | 1,353 | 1,076 | 1,039 | 726.02 |
Other Operating Expenses | 3,168 | 2,880 | 2,514 | 1,791 | 1,609 | 1,200 |
Operating Expenses | 5,899 | 5,290 | 4,538 | 3,471 | 3,277 | 2,416 |
Operating Income | 1,980 | 1,900 | 1,872 | 1,827 | 1,516 | 1,292 |
Interest Expense | -363.78 | -285.43 | -178.11 | -193.72 | -223.15 | -126.56 |
Interest & Investment Income | 13.51 | 13.51 | 8.57 | 22.39 | 25.21 | 49.77 |
Earnings From Equity Investments | 18.38 | 19.01 | 9.78 | 1.75 | 9.57 | 15.47 |
Currency Exchange Gain (Loss) | 168.48 | 168.48 | 108.23 | 66.77 | 84.61 | 62.05 |
Other Non Operating Income (Expenses) | 15.24 | 5.42 | 12.94 | 7.32 | 5.06 | 50.8 |
EBT Excluding Unusual Items | 1,832 | 1,821 | 1,834 | 1,732 | 1,418 | 1,344 |
Gain (Loss) on Sale of Investments | 9.07 | 9.07 | 18.98 | 25.68 | 7.07 | 12.52 |
Gain (Loss) on Sale of Assets | 195.49 | 195.49 | -0.69 | 18.78 | 2.83 | 6.38 |
Other Unusual Items | - | - | - | - | 14.67 | - |
Pretax Income | 2,037 | 2,025 | 1,852 | 1,776 | 1,442 | 1,363 |
Income Tax Expense | 509.42 | 533.02 | 488.07 | 469.26 | 369.62 | 385.8 |
Earnings From Continuing Operations | 1,527 | 1,492 | 1,364 | 1,307 | 1,073 | 976.95 |
Minority Interest in Earnings | - | - | - | - | - | -0.21 |
Net Income | 1,527 | 1,492 | 1,364 | 1,307 | 1,073 | 976.74 |
Net Income to Common | 1,527 | 1,492 | 1,364 | 1,307 | 1,073 | 976.74 |
Net Income Growth | 11.80% | 9.41% | 4.35% | 21.85% | 9.81% | 21.76% |
Shares Outstanding (Basic) | 55 | 55 | 55 | 55 | 55 | 55 |
Shares Outstanding (Diluted) | 55 | 55 | 55 | 55 | 55 | 55 |
Shares Change | 0.18% | 0.07% | 0.08% | -0.05% | 0.33% | 6.37% |
EPS (Basic) | 27.54 | 26.95 | 24.66 | 23.67 | 19.46 | 17.81 |
EPS (Diluted) | 27.54 | 26.93 | 24.63 | 23.62 | 19.38 | 17.70 |
EPS Growth | 11.60% | 9.34% | 4.28% | 21.88% | 9.49% | 14.41% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | 412.55 | -1,996 | -210.69 | -880.28 | 1,187 | -88.67 |
Free Cash Flow Per Share | 7.44 | -36.02 | -3.81 | -15.91 | 21.44 | -1.61 |
Dividend Per Share | - | 0.500 | 0.500 | 0.500 | 0.500 | 0.500 |
Dividend Growth | - | 0% | 0% | 0% | 0% | 0% |
Gross Margin | 29.61% | 30.00% | 30.81% | 28.94% | 28.95% | 25.01% |
Operating Margin | 7.44% | 7.93% | 9.00% | 9.98% | 9.16% | 8.71% |
Profit Margin | 5.74% | 6.23% | 6.56% | 7.14% | 6.48% | 6.59% |
Free Cash Flow Margin | 1.55% | -8.33% | -1.01% | -4.81% | 7.17% | -0.60% |
EBITDA | 2,881 | 2,603 | 2,486 | 2,418 | 2,138 | 1,768 |
EBITDA Margin | 10.82% | 10.86% | 11.95% | 13.21% | 12.91% | 11.92% |
D&A For EBITDA | 900.31 | 703.02 | 613.57 | 591.25 | 621.4 | 476 |
EBIT | 1,980 | 1,900 | 1,872 | 1,827 | 1,516 | 1,292 |
EBIT Margin | 7.44% | 7.93% | 9.00% | 9.98% | 9.16% | 8.71% |
Effective Tax Rate | 25.01% | 26.32% | 26.36% | 26.42% | 25.63% | 28.31% |
Revenue as Reported | 26,847 | 24,187 | 20,843 | 18,380 | 16,614 | 14,950 |